Head-to-head · WeighScore
Rivas Medical Weight Loss vs Zealthy
The verdict
Rivas Medical Weight Loss takes it — 55.6/100 to 46.7/100.
Rivas Medical Weight Loss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rivas Medical Weight Loss is a physician-founded program (Paul Rivas MD LLC) combining 15 in-person clinics with telehealth across Maryland, Virginia, and Florida.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Rivas Medical Weight Loss | Zealthy |
|---|---|---|
| WeighScore | 55.6/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #437 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 3 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #437 · C
Strengths
- Physician-founded (Paul Rivas MD) with 15 clinics plus telehealth
- Flat price for any dose; weekly provider visits included in every payment
- Offers both compounded semaglutide and tirzepatide
Where it loses points
- Expensive: about $498/mo for semaglutide and $715/mo for tirzepatide (billed weekly)
- Only available in Maryland, Virginia, and Florida
- Weekly-visit concierge model requires more frequent engagement than mail-order
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.